Prenumeration
Pharma Equity Group (“PEG” or “the Company”) presented a Q4-report marked by advancements in the clinical development, the addition of two well-experienced board members, and a bolstered IP portfolio. As PEG’s broad Phase II-pipeline progresses further towards potential licensing agreements, the cost base and burn rate are on the rise, as evidenced by the R&D and administrative costs, marking a 26% and 15% increase Q-Q, respectively. PEG has taken critical measures to reinforce the balance sheet and to ensure a solid financial position going into 2024. These measures include the utilization of convertible loans and the securing of a new credit facility after the end of Q4-23. Analyst Group derives a potential present value of DKK 1,448, equivalent to DKK 1.4 (1.4) per share in a Base scenario.
Read the Equity Research Report here
About Analyst Group: One of Sweden's fastest growing equity research boutiques with a focus on small and medium-sized listed companies.
Read more about Analyst Group (Swedish)
This is a press release from Analyst Group regarding the publication of an analysis on Pharma Equity Group. Readers may assume that Analyst Group has received compensation for making the analysis. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.